The average one-year price target for Guangzhou Innogen Pharmaceutical Group Co. (SEHK:2591) has been revised to HK$9.49 / ...

Presenter: Qinghua Wang, Ph.D., Founder, Chairman and Chief Executive Officer of Innogen Innogen's proprietary Efsubaglutide α met the primary endpoint of the Phase IIb ENLIGHT study conducted in ...

From original GLP-1 science to international clinical development, Innogen shares its "from 0 to 1" innovation journey in metabolic diseases PHILADELPHIA, June 22, 2026 /PRNewswire/ -- During the DIA ...

SHANGHAI, Aug. 4, 2026 /PRNewswire/ -- Innogen Pharmaceuticals (HK.2591), a biopharmaceutical company dedicated to innovative drug discovery and industrialization in metabolic diseases, today ...

HONG KONG, April 1, 2026 /PRNewswire/ -- The release of Innogen's inaugural annual report following its Hong Kong listing serves not merely as a financial disclosure, but as a strategic ...

SHANGHAI, July 1 (Reuters) - Chinese drugmaker Innogen expects to complete a late-stage clinical trial of its experimental weight-loss drug candidate next year, its CEO said on Tuesday, the latest ...

Find the Guangzhou Innogen Pharmaceutical financial statements for a comprehensive overview of the company’s financial health. This summary highlights critical numbers from key financial reports, ...

Chinese drugmaker Guangzhou Innogen Pharmaceutical Group Co. tripled on its Hong Kong trading debut, scoring the best first-day performance among all companies that went public in the city this year.

Shares of Guangzhou Innogen Pharmaceutical Group soared on their Hong Kong debut, buoyed by strong investor appetite for China’s pharmaceuticals sector, which has enjoyed rising valuations and solid ...